<DOC>
	<DOC>NCT00163202</DOC>
	<brief_summary>The primary objective of the study is to evaluate the efficacy of atorvastatin 80 mg daily as compared to atorvastatin 10 mg daily in reducing C-reactive protein levels over a 26-week treatment period in subjects with documented coronary artery disease.</brief_summary>
	<brief_title>Comparative Atorvastatin Pleiotropic Effects</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Arteriosclerosis</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<criteria>Male or female subjects of age of majority to &lt; 80 years Subjects with LDLC &gt; 0.5 g/L (1.29 mmol/L) and &lt; 1.5 g/L (3.87 mmol/L), TG &lt; 4.00 g/L (4.56 mmol/L) and hsCRP &gt;1.5 mg/L and &lt; 15 mg/L Subjects with a documented coronary artery disease. Female subjects of childbearing potential without contraception Subjects with secondary hyperlipidemia Diabetic subjects receiving insulin Subjects with a contraindication to statin therapy.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2007</verification_date>
</DOC>